AU2022268348B2 - Binding proteins recognizing hpv16 e7 antigen and uses thereof - Google Patents

Binding proteins recognizing hpv16 e7 antigen and uses thereof Download PDF

Info

Publication number
AU2022268348B2
AU2022268348B2 AU2022268348A AU2022268348A AU2022268348B2 AU 2022268348 B2 AU2022268348 B2 AU 2022268348B2 AU 2022268348 A AU2022268348 A AU 2022268348A AU 2022268348 A AU2022268348 A AU 2022268348A AU 2022268348 B2 AU2022268348 B2 AU 2022268348B2
Authority
AU
Australia
Prior art keywords
cell
tcr
host cell
binding protein
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022268348A
Other languages
English (en)
Other versions
AU2022268348A1 (en
Inventor
Antoine J. BOUDOT
Sonal JANGALWE
Gavin Macbeath
Ribhu NAYAR
Daniel POLLACKSMITH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tscan Therapeutics Inc
Original Assignee
Tscan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tscan Therapeutics Inc filed Critical Tscan Therapeutics Inc
Publication of AU2022268348A1 publication Critical patent/AU2022268348A1/en
Application granted granted Critical
Publication of AU2022268348B2 publication Critical patent/AU2022268348B2/en
Priority to AU2024200496A priority Critical patent/AU2024200496A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
AU2022268348A 2021-11-10 2022-11-10 Binding proteins recognizing hpv16 e7 antigen and uses thereof Active AU2022268348B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024200496A AU2024200496A1 (en) 2021-11-10 2024-01-26 Binding proteins recognizing hpv16 e7 antigen and uses thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163277901P 2021-11-10 2021-11-10
US63/277,901 2021-11-10
US202263317326P 2022-03-07 2022-03-07
US63/317,326 2022-03-07
US202263342479P 2022-05-16 2022-05-16
US63/342,479 2022-05-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024200496A Division AU2024200496A1 (en) 2021-11-10 2024-01-26 Binding proteins recognizing hpv16 e7 antigen and uses thereof

Publications (2)

Publication Number Publication Date
AU2022268348A1 AU2022268348A1 (en) 2023-05-25
AU2022268348B2 true AU2022268348B2 (en) 2024-01-18

Family

ID=86336427

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022268348A Active AU2022268348B2 (en) 2021-11-10 2022-11-10 Binding proteins recognizing hpv16 e7 antigen and uses thereof
AU2024200496A Pending AU2024200496A1 (en) 2021-11-10 2024-01-26 Binding proteins recognizing hpv16 e7 antigen and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024200496A Pending AU2024200496A1 (en) 2021-11-10 2024-01-26 Binding proteins recognizing hpv16 e7 antigen and uses thereof

Country Status (11)

Country Link
US (1) US20230272049A1 (https=)
EP (1) EP4430066A4 (https=)
JP (1) JP2024544903A (https=)
KR (1) KR20240112996A (https=)
AU (2) AU2022268348B2 (https=)
CA (1) CA3237646A1 (https=)
CO (1) CO2024007117A2 (https=)
IL (1) IL312550A (https=)
MX (1) MX2024005743A (https=)
TW (1) TW202325722A (https=)
WO (1) WO2023086477A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116660431B (zh) * 2023-05-30 2025-08-12 詹晓凯 来那度胺在尿液中的代谢物及应用
GB202311170D0 (en) * 2023-07-20 2023-09-06 Univ Oxford Innovation Ltd Antigen binding polypeptides
TW202547854A (zh) * 2024-04-08 2025-12-16 美商帝斯肯醫療公司 Ｍａｇｅｃ２免疫原性肽、識別ｍａｇｅｃ２免疫原性肽之結合蛋白及其用途
WO2026058153A2 (en) * 2024-09-10 2026-03-19 BioNTech SE Hpv-16 t cell receptor uses and compositions thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018067618A1 (en) * 2016-10-03 2018-04-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
WO2019195486A1 (en) * 2018-04-05 2019-10-10 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
US20210130432A1 (en) * 2014-05-29 2021-05-06 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Anti-human papillomavirus 16 e7 t cell receptors
WO2021139698A1 (zh) * 2020-01-06 2021-07-15 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的t细胞受体及其编码序列
WO2021170115A1 (zh) * 2020-02-28 2021-09-02 香雪生命科学技术（广东）有限公司 一种识别hpv的t细胞受体
WO2021204287A1 (zh) * 2020-04-10 2021-10-14 香雪生命科学技术（广东）有限公司 一种识别hpv16的高亲和力tcr

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11702459B2 (en) * 2017-03-07 2023-07-18 Universität Basel MR1 restricted T cell receptors for cancer immunotherapy
JP2020537515A (ja) * 2017-10-03 2020-12-24 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
CN112912391A (zh) * 2018-10-25 2021-06-04 昆士兰医学研究所理事会 T细胞受体及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210130432A1 (en) * 2014-05-29 2021-05-06 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Anti-human papillomavirus 16 e7 t cell receptors
WO2018067618A1 (en) * 2016-10-03 2018-04-12 Juno Therapeutics, Inc. Hpv-specific binding molecules
WO2019195486A1 (en) * 2018-04-05 2019-10-10 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same
WO2021139698A1 (zh) * 2020-01-06 2021-07-15 香雪生命科学技术（广东）有限公司 一种识别hpv抗原的t细胞受体及其编码序列
WO2021170115A1 (zh) * 2020-02-28 2021-09-02 香雪生命科学技术（广东）有限公司 一种识别hpv的t细胞受体
WO2021204287A1 (zh) * 2020-04-10 2021-10-14 香雪生命科学技术（广东）有限公司 一种识别hpv16的高亲和力tcr

Also Published As

Publication number Publication date
AU2024200496A1 (en) 2024-02-15
AU2022268348A1 (en) 2023-05-25
JP2024544903A (ja) 2024-12-05
KR20240112996A (ko) 2024-07-19
TW202325722A (zh) 2023-07-01
IL312550A (en) 2024-07-01
EP4430066A2 (en) 2024-09-18
US20230272049A1 (en) 2023-08-31
EP4430066A4 (en) 2025-12-24
CO2024007117A2 (es) 2024-09-19
CA3237646A1 (en) 2023-05-19
WO2023086477A2 (en) 2023-05-19
MX2024005743A (es) 2024-05-27
WO2023086477A3 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
AU2022268348B2 (en) Binding proteins recognizing hpv16 e7 antigen and uses thereof
AU2022268347B2 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
JP2024544903A5 (https=)
JP2023549765A (ja) Ｈａ－１抗原を認識する結合タンパク質及びその使用
CA3216553A1 (en) Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
AU2024278650A1 (en) Prame immunogenic peptides, binding proteins recognizing prame immunogenic peptides, and uses thereof
AU2023241307B2 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
WO2025090850A1 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
CN118510797A (zh) 识别hpv16 e7抗原的结合蛋白和其用途
WO2025217028A1 (en) Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
AU2026202663A1 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
CN118613497A (zh) Magea1免疫原性肽、识别magea1免疫原性肽的结合蛋白和其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)